Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Japan’s Takeda Pharmaceutical Co said on Friday an alliance of drugmakers that it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID-19 after months of regulatory delays.
The phase 3 trial from the group, referred to as the CoVIg Plasma Alliance, intends to enroll 500 adult patients from the USA, Mexico and 16 other countries, according to a statement.
Patients will be treated with Gilead Science Inc’s Remdesivir alongside the plasma treatment, which will be given by CSL Behring, Takeda and two other businesses.
“We’re optimistic that data from the clinical trial will be available before the end of the year,” Bill Mezzanotte, chief medical officer of CSL Behring, said in the release.
The group had aimed to start the clinical trial in July, but it was postponed pending regulatory approval.
The alliance, which also includes Germany’s Biotest AG and Octapharma Plasma, is working on a hyperimmune globulin therapy derived from the blood plasma of people who have recovered from COVID-19.
It gives a standardised dose of antibodies and does not need to be limited to patients with matching blood types.
